Cadila recalls tens of thousands of bottles of antidepressant


The manufacturing issues continue to mount for India’s Cadila Healthcare. The drugmaker, which last year was hit with an FDA warning letter for two of its Indian plants, is now recalling several hundred thousand bottles of an antidepressant made at one of those plants.

According to the most recent FDA Enforcement Report, Cadila is recalling 26 lots of venlafaxine HCL ER capsules that accounted for 223,776 bottles, as well as another 9 lots for which it did not specify a bottle count.

The report says the drugs were manufactured in Ahmedabad and failed dissolution specs when retained samples were tested. Venlafaxine is an antidepressant used to treat major depressive disorder, anxiety and panic disorder.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

In January, Cadila reported that it received a warning letter for a formulation facility, also in Moraiya, as well as its Zyfine API plant in Ahmedabad. Cadila insisted at the time that it takes quality seriously and will do what is necessary to meet FDA expectations. Among other issues, the FDA raised concerns about manufacturing of warfarin products, saying Cadila never got to the root cause of issues.

Several months later, a World Health Organization report indicated that Cadila had suspended manufacturing and recalled all the batches of Lyssavac-N (antirabies vaccine) manufactured after April 2015 inspections when it was found faking data about contamination issues at the facility.

- access the Enforcement Report here

Related Articles: 
Cadila is latest Indian drugmaker to feel sting of an FDA warning letter 
Cadila faces new regulatory problems as WHO piles on the pain 
FDA warning letter tells Cadila to resolve problems with warfarin production

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.